These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6798759)

  • 1. Accumulative effect of DDAVP and heparin in increasing plasma factor VIII levels.
    Rock G; Palmer DS
    Vox Sang; 1981; 41(1):56-60. PubMed ID: 6798759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII-related activities after 1-deamino-8-D-arginine vasopressin in multicentric reticulohistiocytosis.
    Taddeo U; Trotta F; Menegale G; Ballerini G
    Ric Clin Lab; 1984; 14(1):37-9. PubMed ID: 6427880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved yields of factor VIII from heparinized plasma.
    Rock GA; Cruickshank WH; Tackaberry ES; Palmer DS
    Vox Sang; 1979; 36(5):294-300. PubMed ID: 462918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
    Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of factor VIII after administration of DDAVP to conscious dogs.
    Vilhardt H; Barth T; Falch J; Nilsson IM
    Thromb Res; 1987 Sep; 47(5):585-91. PubMed ID: 3118500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.
    Lethagen S; Harris AS; Sjörin E; Nilsson IM
    Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
    Muhm M; Grois N; Kier P; Stümpflen A; Kyrle P; Pabinger I; Bettelheim P; Hinterberger W; Lechner K
    Haemostasis; 1990; 20(1):15-20. PubMed ID: 2108912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDAVP: does the drug have a direct effect on the vessel wall?
    Barnhart MI; Chen S; Lusher JM
    Thromb Res; 1983 Jul; 31(2):239-53. PubMed ID: 6415852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.
    Ibbotson SH; Grant PJ; Kerry R; Findlay VS; Prentice CR
    Thromb Haemost; 1991 Jan; 65(1):64-6. PubMed ID: 1902596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on the properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) in normal individuals (author's transl)].
    Takahashi H; Itoh M; Kobayashi I; Hattori A; Takahashi K; Sakuragawa N; Shibata A; Tsukada T
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):907-17. PubMed ID: 6785953
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.
    Mannucci PM; Vicente V; Alberca I; Sacchi E; Longo G; Harris AS; Lindquist A
    Thromb Haemost; 1987 Dec; 58(4):1037-9. PubMed ID: 3127916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of VIII:C in plasma: the dependence on protease activity and calcium.
    Rock GA; Cruickshank WH; Tackaberry ES; Ganz PR; Palmer DS
    Thromb Res; 1983 Mar; 29(5):521-35. PubMed ID: 6407138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome.
    Schmitz-Huebner U; Balleisen L; Arends P; Pollmann H; Sutor AH
    Haemostasis; 1980; 9(4):204-13. PubMed ID: 6772527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors.
    Palmer DS; Harris AS; Tittley P; Rock G
    Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons.
    Nilsson IM; Mikaelsson M; Vilhardt H
    Scand J Haematol; 1982 Jul; 29(1):70-4. PubMed ID: 6812213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand's disease and hemophilia.
    Köhler M; Hellstern P; Reiter B; von Blohn G; Wenzel E
    Klin Wochenschr; 1984 Jun; 62(11):543-8. PubMed ID: 6471780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
    Mannucci PM; Canciani MT; Rota L; Donovan BS
    Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.